56 related articles for article (PubMed ID: 15161690)
1. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
Stadler WM; Cao D; Vogelzang NJ; Ryan CW; Hoving K; Wright R; Karrison T; Vokes EE
Clin Cancer Res; 2004 May; 10(10):3365-70. PubMed ID: 15161690
[TBL] [Abstract][Full Text] [Related]
2. SU5416 does not attenuate early RV angiogenesis in the murine chronic hypoxia PH model.
Peloquin GL; Johnston L; Damarla M; Damico RL; Hassoun PM; Kolb TM
Respir Res; 2019 Jun; 20(1):123. PubMed ID: 31208454
[TBL] [Abstract][Full Text] [Related]
3. Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer.
Holtz DO; Krafty RT; Mohamed-Hadley A; Zhang L; Alagkiozidis I; Leiby B; Guo W; Gimotty PA; Coukos G
J Transl Med; 2008 Jan; 6():2. PubMed ID: 18182107
[TBL] [Abstract][Full Text] [Related]
4. Serum Levels of Stromal Cell-Derived Factor-1α and Vascular Endothelial Growth Factor Predict Clinical Outcomes in Head and Neck Squamous Cell Carcinoma Patients Receiving TPF Induction Chemotherapy.
Chen YH; Chien CY; Wang YM; Li SH
Biomedicines; 2022 Mar; 10(4):. PubMed ID: 35453553
[TBL] [Abstract][Full Text] [Related]
5. Combined detection of peripheral blood VEGF and inflammation biomarkers to evaluate the clinical response and prognostic prediction of non-operative ESCC.
Ma Y; Su X; Li X; Zhi X; Jiang K; Xia J; Li H; Yan C; Zhou L
Sci Rep; 2021 Jul; 11(1):15305. PubMed ID: 34315926
[TBL] [Abstract][Full Text] [Related]
6. Signaling Pathways That Control Apoptosis in Prostate Cancer.
Ali A; Kulik G
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668112
[TBL] [Abstract][Full Text] [Related]
7. Immuno-PET imaging of VEGFR-2 expression in prostate cancer with
Li M; Jiang D; Barnhart TE; Cao T; Engle JW; Chen W; Cai W
Am J Cancer Res; 2019; 9(9):2037-2046. PubMed ID: 31598404
[TBL] [Abstract][Full Text] [Related]
8. The crucial role of blood VEGF kinetics in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy.
Chen YH; Lu HI; Lo CM; Wang YM; Chou SY; Hsiao CC; Huang CC; Shih LH; Chen SW; Li SH
BMC Cancer; 2018 Aug; 18(1):837. PubMed ID: 30126380
[TBL] [Abstract][Full Text] [Related]
9. VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy.
Tsourlakis MC; Khosrawi P; Weigand P; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Krech T; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S
Int J Mol Sci; 2015 Apr; 16(4):8591-606. PubMed ID: 25894226
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor receptor inhibitor SU5416 suppresses lymphocyte generation and immune responses in mice by increasing plasma corticosterone.
Grailer JJ; Steeber DA
PLoS One; 2013; 8(9):e75390. PubMed ID: 24066177
[TBL] [Abstract][Full Text] [Related]
11. Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.
Alcorn S; Walker AJ; Gandhi N; Narang A; Wild AT; Hales RK; Herman JM; Song DY; Deweese TL; Antonarakis ES; Tran PT
Int J Mol Sci; 2013 Jul; 14(7):14800-32. PubMed ID: 23863691
[TBL] [Abstract][Full Text] [Related]
12. The VEGF pathway in cancer and disease: responses, resistance, and the path forward.
Kieran MW; Kalluri R; Cho YJ
Cold Spring Harb Perspect Med; 2012 Dec; 2(12):a006593. PubMed ID: 23209176
[TBL] [Abstract][Full Text] [Related]
13. Peptoid-based PET imaging of vascular endothelial growth factor receptor (VEGFR) expression.
Hao G; Hajibeigi A; León-Rodríguez LM; Oz OK; Sun X
Am J Nucl Med Mol Imaging; 2011; 1(1):65-75. PubMed ID: 23133797
[TBL] [Abstract][Full Text] [Related]
14. Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer.
Saylor PJ; Mahmood U; Kunawudhi A; Smith MR; Palmer EL; Michaelson MD
J Nucl Med; 2012 Nov; 53(11):1670-5. PubMed ID: 22984218
[TBL] [Abstract][Full Text] [Related]
15. Future perspectives of prostate cancer therapy.
Gururajan M; Posadas EM; Chung LW
Transl Androl Urol; 2012 Jan; 1(1):19-32. PubMed ID: 22773967
[TBL] [Abstract][Full Text] [Related]
16. The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients.
Sonpavde G; Bellmunt J; Schutz F; Choueiri TK
Curr Oncol Rep; 2012 Aug; 14(4):295-306. PubMed ID: 22532265
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.
Bousquet G; Alexandre J; Le Tourneau C; Goldwasser F; Faivre S; de Mont-Serrat H; Kaiser R; Misset JL; Raymond E
Br J Cancer; 2011 Nov; 105(11):1640-5. PubMed ID: 22027711
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylated pVEGFR2/KDR receptor expression in uveal melanomas: relation with HIF2α and survival.
Giatromanolaki A; Sivridis E; Bechrakis NE; Willerding G; St Charitoudis G; Foerster MH; Gatter KC; Harris AL; Koukourakis MI
Clin Exp Metastasis; 2012 Jan; 29(1):11-7. PubMed ID: 21984395
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor receptor-2 in breast cancer.
Guo S; Colbert LS; Fuller M; Zhang Y; Gonzalez-Perez RR
Biochim Biophys Acta; 2010 Aug; 1806(1):108-21. PubMed ID: 20462514
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis inhibitors in the treatment of prostate cancer.
Kluetz PG; Figg WD; Dahut WL
Expert Opin Pharmacother; 2010 Feb; 11(2):233-47. PubMed ID: 20088745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
